WallStreetZenWallStreetZen

NASDAQ: NEXI
Neximmune Inc Stock

$3.13-0.03 (-0.95%)
Updated May 23, 2024
NEXI Price
$3.13
Fair Value Price
$2.99
Market Cap
$4.29M
52 Week Low
$1.25
52 Week High
$28.70
P/E
-0.13x
P/B
1.56x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$25.86M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
2.2
Operating Cash Flow
-$22M
Beta
1.07
Next Earnings
May 29, 2024
Ex-Dividend
N/A
Next Dividend
N/A

NEXI Overview

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.

Zen Score

Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NEXI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

NEXI ($3.13) is overvalued by 4.79% relative to our estimate of its Fair Value price of $2.99 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
NEXI ($3.13) is not significantly undervalued (4.79%) relative to our estimate of its Fair Value price of $2.99 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
NEXI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NEXI due diligence checks available for Premium users.

Be the first to know about important NEXI news, forecast changes, insider trades & much more!

NEXI News

Valuation

NEXI fair value

Fair Value of NEXI stock based on Discounted Cash Flow (DCF)
Price
$3.13
Fair Value
$2.99
Overvalued by
4.82%
NEXI ($3.13) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NEXI ($3.13) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NEXI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

NEXI price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.13x
Industry
11.17x
Market
31.54x

NEXI price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.56x
Industry
6.06x
NEXI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

NEXI's financial health

Profit margin

Revenue
$0.0
Net Income
-$3.1M
Profit Margin
0%
NEXI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$9.0M
Liabilities
$6.0M
Debt to equity
2.2
NEXI's short-term assets ($6.04M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NEXI's short-term assets ($6.04M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NEXI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$2.4M
Investing
$522.6k
Financing
$3.1M
NEXI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

NEXI vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
NEXI$4.29M-0.98%-0.13x1.56x
ENSC$4.47M-7.54%-0.16x1.19x
ALZN$4.08M-4.19%-0.32x-0.96x
TCON$4.07M+1.33%1.75x-2.31x
MYMD$4.62M0.00%-0.21x0.46x

Neximmune Stock FAQ

What is Neximmune's quote symbol?

(NASDAQ: NEXI) Neximmune trades on the NASDAQ under the ticker symbol NEXI. Neximmune stock quotes can also be displayed as NASDAQ: NEXI.

If you're new to stock investing, here's how to buy Neximmune stock.

What is the 52 week high and low for Neximmune (NASDAQ: NEXI)?

(NASDAQ: NEXI) Neximmune's 52-week high was $28.70, and its 52-week low was $1.25. It is currently -89.1% from its 52-week high and 150.32% from its 52-week low.

How much is Neximmune stock worth today?

(NASDAQ: NEXI) Neximmune currently has 1,371,051 outstanding shares. With Neximmune stock trading at $3.13 per share, the total value of Neximmune stock (market capitalization) is $4.29M.

Neximmune stock was originally listed at a price of $633.25 in Feb 12, 2021. If you had invested in Neximmune stock at $633.25, your return over the last 3 years would have been -99.51%, for an annualized return of -82.97% (not including any dividends or dividend reinvestments).

How much is Neximmune's stock price per share?

(NASDAQ: NEXI) Neximmune stock price per share is $3.13 today (as of May 23, 2024).

What is Neximmune's Market Cap?

(NASDAQ: NEXI) Neximmune's market cap is $4.29M, as of May 24, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Neximmune's market cap is calculated by multiplying NEXI's current stock price of $3.13 by NEXI's total outstanding shares of 1,371,051.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.